Seres’ visionary team has been at the forefront of microbiome therapeutics for over a decade.
Pioneering microbiome therapeutics for serious diseases
Seres Therapeutics is a commercial biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human microbiome.
We are an exceptional team of drug development and microbiome experts. Our leadership team, board of directors and scientific advisory board have vast experience in the discovery, development, regulatory approval, and successful commercialization of a wide range of therapeutic products.
Our mission is to transform the lives of patients worldwide with revolutionary microbiome therapeutics.
Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has over 20 years of experience working in leadership roles in biotechnology finance, corporate development and capital markets. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business unit finance, corporate finance and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff serves on the board of directors of Sigilon Therapeutics, Inc. Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his MBA with a concentration in finance from the Johnson Graduate School of Management at Cornell University.
David Arkowitz is the Executive Vice President, Chief Financial Officer and Head of Business Development of Seres. Prior to joining Seres, Mr. Arkowitz served as the Chief Financial Officer of Flexion Therapeutics, a biotechnology company, since 2018 and has responsibility for the finance and accounting, corporate communications and investor relations, information technology, and Chemistry, Manufacturing and Controls (CMC) functions. Mr. Arkowitz brings more than 30 years of finance and operations leadership experience in the life sciences and biotechnology industries. Prior to joining Flexion, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, Inc., a biotechnology company that was acquired by Otsuka Pharmaceutical Co., where he led the finance, business development, corporate planning, and other functions. Mr. Arkowitz currently serves on the board of directors and as chair of the audit committee of F-star Therapeutics, Inc., a public biopharmaceutical company, and on the board of directors of Yumanity Therapeutics, Inc., a public biopharmaceutical company. Previously, Mr. Arkowitz was CFO at Mascoma Corporation, AMAG Pharmaceuticals Inc., and Idenix Pharmaceuticals LLC and held additional leadership positions within each company. Preceding his tenure at Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller of the U.S. operations, Controller of the global research and development division, and CFO of the Canadian subsidiary. He obtained his B.A. in mathematics at Brandeis University and his M.B.A. in finance at Columbia University Business School.
Paula Cloghessy, SPHR, SHRM-SCP, has joined Seres as Executive Vice President, Chief People Officer. Paula brings to Seres more than 20 years of human resources expertise with broad business experience leading human resources organizations in the biotechnology and pharmaceutical industries, including a successful track record of translating organizational objectives into dynamic HR programs and infrastructure. She most recently served as Chief People Officer at Translate Bio, Inc., where she led the talent architecture and people strategy. Throughout her career in biotech, Paula has strived to prioritize the employee environment with an emphasis on curating talent and fostering an adaptive and inclusive culture. Prior to Translate, she served as vice president of human resources at Joule Unlimited Technologies, Inc. She has also held human resources positions at Interleukin Genetics, Inc. and NUCRYST Pharmaceuticals, Inc. Paula holds a B.A. in psychology from the University of Massachusetts Boston and senior human resources certifications including SPHR and SHRM-SCP.
Thomas J. DesRosier is the Executive Vice President, Chief Legal Officer and Secretary of Seres. He brings more than 30 years of experience in the biopharmaceutical industry. Prior to joining Seres, he served as Chief Legal and Administrative Officer at ARIAD Pharmaceuticals, and prior to that held the same position at Cubist Pharmaceuticals, where he led the negotiation of the acquisition of Cubist by Merck. Previous to that, he served as Senior Vice President and General Counsel, North America of Sanofi, a position he assumed in 2011 after Sanofi acquired Genzyme Corporation, where he was Senior Vice President and Chief Legal Officer. Prior to his 12-year tenure at Genzyme, Mr. DesRosier held senior legal positions at Wyeth Pharmaceuticals, predecessor Genetic Institute, and E.I. DuPont de Nemours. Mr. DesRosier serves on the board of directors of Avanir Pharmaceuticals where he is Chairman of both the Audit Committee and Compliance Committee. He received his B.A. in chemistry from the University of Vermont and his J.D. from Wake Forest University School of Law.
David Ege is the Executive Vice President and Chief Technology Officer of Seres. He has more than 15 years of experience in the pharmaceutical industry, with a focus on vaccine and biologics manufacturing, facility development and process optimization. Prior to joining Seres, Dr. Ege had been at Merck since 2003, in a variety of technical and leadership roles in R&D and manufacturing, in the U.S. and Switzerland. His most recent role was global lead for digital strategy in Merck’s Manufacturing Division. From 2015-2019, Dr. Ege served as Executive Director of Vaccines & Biologics Manufacturing at Merck’s plant in Elkton, VA where he led bulk manufacturing operations for the Gardasil® and Gardasil9® cervical cancer vaccines, as well as adjuvants and Cancidas® – a broad-based anti-fungal medicine made by fermentation. He has contributed to the successful first-in-class licensure and launch of cervical cancer vaccines, Gardasil® (2006) and Gardasil9® (2014), and a breakthrough cancer immunotherapy, Keytruda® (2014). He graduated summa cum laude from Princeton with a BSE in chemical engineering and earned his Ph.D. in chemical engineering from the University of Pennsylvania. While at Penn, Dave also worked in the University’s Center for Technology Transfer and served as President of the Penn Biotech Group.
Matthew Henn is the Executive Vice President and Chief Scientific Officer of Seres. He has over 20 years of combined research experience in microbial ecology, genomics and bioinformatics that spans both environmental and human disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics including all of Seres’ product candidates and has authored over 65 peer-reviewed publications. His research has focused on microbial physiology and the functional role of microbes in both environmental and human disease applications, and on the development of genomic and functional tools to study microbial systems. Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. He has served on various NIH working groups on antimicrobial resistance and microbiome research, as a scientific advisor for NIH’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of various peer-reviewed journals. He currently serves on the scientific advisory board of Growcentia, Inc., an agricultural microbiome company. Dr. Henn earned his B.S. in ecology and evolutionary sciences from the University of New Hampshire and his Ph.D. from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as an NSF Postdoctoral Fellow at Duke University.
Lisa Von Moltke, M.D., is the Executive Vice President and Chief Medical Officer at Seres. She has extensive experience in directing successful development programs, leading clinical teams and interacting with regulatory agencies across multiple areas of medicine. Prior to joining Seres, Dr. Von Moltke worked for Alkermes, Inc., where she served in roles of increasing seniority, culminating as Senior Vice President and Head of Clinical Development. Prior to joining Alkermes, Dr. Von Moltke served as Vice President Clinical Pharmacology at Sanofi/Genzyme Corporation, where she also served as U.S. Head Clinical & Exploratory Pharmacology Sciences (CEP) and Early Development and later as Head CEP for Japan and China regions. Earlier in her career, Dr. Von Moltke served as Head, Translational Medicine for the Takeda Oncology Company. She has served as President of the American College of Clinical Pharmacology and as the Editor-in-Chief of The Journal of Clinical Pharmacology. Dr. Von Moltke earned a B.A. at Wellesley College and her M.D. from Michigan State University, College of Human Medicine.
Terri Young is the Executive Vice President, Chief Commercial and Strategy Officer at Seres Therapeutics. Prior to joining Seres, Dr. Young served as Vice President, Global Commercial Strategy at Sage Therapeutics, where she led development of Sage’s global commercial capabilities, including global marketing, insights and analytics and new product planning. Previously, she held commercial leadership roles of increasing responsibility at Bristol-Myers Squibb, culminating in her role as Vice President and General Manager, Cardiovascular, in which she led the global ELIQUIS® business to become the company’s largest product by revenue. Earlier in her career, Dr. Young held marketing and sales roles at GlaxoSmithKline, where she catalyzed growth for the company’s Urology, Diabetes and NeuroHealth organizations. Dr. Young received her B.S. in pharmacy and her Ph.D. in healthcare marketing from the University of South Carolina. Dr. Young is a member of the Women in Bio and Healthcare Businesswomen’s Association, and served on the Advisory Board of the Healthcare Businesswomen’s Association.
President, Chief Executive Officer
Eric Shaff is the President and Chief Executive Officer of Seres. Mr. Shaff was previously the Executive Vice President, Chief Operating and Financial Officer of Seres. He has over 20 years of experience working in leadership roles in biotechnology, finance, corporate development, and capital markets. Prior to joining Seres, he was Vice President, Corporate Finance, at Momenta Pharmaceuticals, where he helped manage Momenta’s accounting, finance, planning, and procurement functions, as well as contributing to Momenta’s investor relations efforts. Prior to joining Momenta, Mr. Shaff was Vice President, Finance, of Genzyme’s Rare Genetic Disease Division, responsible for a global portfolio of products. Mr. Shaff held several positions at Genzyme in business-unit finance, corporate finance, and corporate development. Prior to Genzyme, Mr. Shaff worked in corporate finance at Pfizer and worked in investment banking for Broadview International (now Jefferies LLC). Mr. Shaff serves on the board of directors of Sigilon Therapeutics, Inc. Mr. Shaff earned his B.A. from the University of Pennsylvania in political science and economics and his MBA with a concentration in finance from the Johnson Graduate School of Management at Cornell University.
Chairman of the Board of Directors
Stephen Berenson is a Managing Partner at Flagship Pioneering and member of the firm’s Resource Allocation and Management Committees. Prior to Flagship, Mr. Berenson spent over 3 decades in various roles as an investment banker at J.P. Morgan. During his last 12 years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking. He was also cofounder of J.P. Morgan’s Global Strategic Advisory Council and cofounder of the firm’s Board Initiative. Mr. Berenson is chairman of the board of directors of Cellarity, and he also serves on the boards of directors of Moderna, Inc. and Repertoire Immune Medicines.
Mr. Berenson earned his S.B. in mathematics from the Massachusetts Institute of Technology.
Dennis Ausiello, M.D.
Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School; Chair of Medicine, Emeritus at Massachusetts General Hospital
Dennis A. Ausiello is the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School. He is concurrently the Director, Emeritus of the Harvard Medical School’s M.D./Ph.D. Program. Dr. Ausiello is also Chair of Medicine, Emeritus, and Director of the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital. Dr. Ausiello was the former Lead Director of the board of directors at Pfizer, Inc. Previously, Dr. Ausiello served as an editor of Cecil’s Textbook of Medicine. Dr. Ausiello serves on the boards of directors of Alnylam Pharmaceuticals and Rani Therapeutics Holdings, Inc., and previously served on the board of directors of Pfizer, where he currently serves on the advisory board. He received his B.S. from Harvard College and his M.D. from the University of Pennsylvania School of Medicine. Throughout his career, Dr. Ausiello has made substantial contributions to the study of epithelial biology in the areas of membrane protein trafficking, ion channel regulation, and signal transduction, and has published numerous articles, book chapters, and textbooks.
Executive Chairman, i20 Therapeutics, Former Chairman, President, and CEO, Intarcia Therapeutics, Inc.
Kurt Graves serves as Executive Chairman of i20 Therapeutics. Mr. Graves is the former Chairman, President, and Chief Executive Officer of Intarcia. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer, and Head of Corporate and Strategic Development at Vertex Pharmaceuticals. Prior to his tenure at Vertex, he spent nearly 10 years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Mr. Graves also previously held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals, where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. Mr. Graves earned his B.S. in biology from Hillsdale College and has attended executive leadership programs at Harvard University, the University of Pennsylvania Wharton School of Management, and University of Michigan.
Executive Partner, Flagship Pioneering
Paul Biondi serves as Executive Partner and President of Pioneering Medicines at Flagship Pioneering where he has been since November 2019. Mr. Biondi joined Flagship Pioneering following a 17-year tenure at Bristol-Myers Squibb (BMS) where he was most recently the Senior Vice President of Strategy and Business Development. Prior to serving in the role of Senior Vice President of Strategy, from 2002 to 2015, Mr. Biondi held a series of other leadership roles within BMS’ Research and Development organization overseeing strategy, portfolio, and project management, as well as clinical and business operations. Mr. Biondi holds a bachelor’s degree from Dartmouth College and an MBA from the J.L. Kellogg School of Management at Northwestern University.
Former Senior Vice President of Business Development and Corporate Licensing, Merck
Richard Kender most recently served as Senior Vice President of Business Development and Corporate Licensing at Merck. Mr. Kender spent his entire professional career at the company in various corporate roles of increasing responsibility. At Merck, Mr. Kender was involved in more than 100 business development and licensing transactions. Currently, he also serves on the boards of directors of Poxel, Bicycle Therapeutics PLC and ReViral Ltd. Mr. Kender earned his B.S. in accounting from Villanova University and his MBA from Fairleigh Dickinson University.
Willard Dere, M.D. FACP
Associate Vice President for Research and Professor of Internal Medicine, University of Utah Health Sciences
Willard H. Dere, M.D., joined the University of Utah Health Sciences Center in November 2014 as the Executive Director of Personalized Health and Professor of Internal Medicine. He currently serves roles as Associate Vice President for Research, codirector of the Utah Center for Clinical and Translational Science, and codirector of the Center for Genomic Medicine. Prior to rejoining academia, Dr. Dere was in the biopharmaceutical industry for 25 years, first at Eli Lilly, then at Amgen, where he was most recently Head of Global Development and Chief Medical Officer. Dr. Dere led the clinical development of raloxifene, rPTH 1-34, denosumab, and other drugs in a broad range of therapeutic areas. Dr. Dere serves on the boards of directors of BioMarin Pharmaceutical Inc., Radius Health, and Mersana Therapeutics, Inc. Dr. Dere received his undergraduate and medical degrees from the University of California, Davis, completed his internal medicine residency training at the University of Utah, and his postdoctoral training in endocrinology and metabolism at the University of California, San Francisco. He was awarded the 2008 Transformational Leadership Award from UC Davis School of Medicine, multiple teaching awards from the University of Utah School of Medicine, and is a fellow in the American College of Physicians.
Claire M. Fraser, Ph.D.
Director, Institute for Genome Sciences
Claire M. Fraser, Ph.D., is the director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine in Baltimore, Maryland. From 1998 to 2007, she served as president and director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies. Dr. Fraser has served on the board of directors of Becton, Dickinson, and Company since 2006, and previously served as the Chair of the Board and a director of the American Association for the Advancement of Science. Dr. Fraser received her bachelor’s degree in Biology from Rensselaer Polytechnic Institute and her Ph.D. in Pharmacology from State University of New York-Buffalo.
Elhanan Borenstein, Ph.D.
Professor of Computer Science and of Medicine, Tel Aviv University
Andrew Goodman, Ph.D.
C.N.H. Long Professor of Microbial Pathogenesis and Director of the Microbial Sciences Institute, Yale University
Curtis Huttenhower, Ph.D.
Professor of Computational Biology and Bioinformatics, Department of Biostatistics, School of Public Health, Harvard University
Robert Jenq, M.D.
Medical Oncologist; Assistant Professor at MD Anderson Cancer Center
Marcel van den Brink, M.D., Ph.D.
Head, Division of Hematologic Malignancies; Alan N. Houghton Professor in Immunology; Member, Memorial Sloan-Kettering Cancer Center
Mark Wilcox, M.D.
Professor of Medical Microbiology, University of Leeds, and Consultant Clinical Microbiologist, Leeds Teaching Hospitals NHS Trust
Seres’ collaboration with Nestlé Health Science, announced Jan. 11, 2016, pertains to C. difficile and IBD programs for markets outside of North America. SER-109 co-commercialization agreement for North America with Nestlé Health Science announced July 1, 2021.
Seres’ collaboration with Memorial Sloan Kettering Cancer Center (MSK), announced May 12, 2016, is related to the discovery and development of microbiome therapeutics, specifically: (1) improving the morbidity and mortality outcomes of patients undergoing hematopoietic stem cell transplantation (HSCT) for treatment of cancer through the prevention of transplant-related infections and graft-versus-host disease (GVHD); and (2) increasing the efficacy and safety of checkpoint inhibitors used for immuno-oncology treatment.